Atjaunināt sīkdatņu piekrišanu

Countering the Pandemic Threat Through Global Coordination on Vaccines: The Influenza Imperative [Mīkstie vāki]

  • Formāts: Paperback / softback, 236 pages, height x width: 229x152 mm
  • Izdošanas datums: 27-Feb-2022
  • Izdevniecība: National Academies Press
  • ISBN-10: 0309088704
  • ISBN-13: 9780309088701
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 63,82 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 236 pages, height x width: 229x152 mm
  • Izdošanas datums: 27-Feb-2022
  • Izdevniecība: National Academies Press
  • ISBN-10: 0309088704
  • ISBN-13: 9780309088701
Citas grāmatas par šo tēmu:
The COVID-19 pandemic has laid bare the fragility of the global system of preparedness and response to pandemics and the fragmentation of our research and development ecosystem. The pandemic has provided a disruptive moment to advance new norms and frameworks for influenza. It also has demonstrated how innovative global public-private partnerships and coordination mechanisms can lead to rapid successes in viral vaccine research, manufacturing, and risk pooling.



Countering the Pandemic Threat Through Global Coordination on Vaccines identifies ways to strengthen pandemic and seasonal influenza global coordination, partnerships, and financing. This report presents seven overarching recommendations for how the urgent influenza threat should be conceptualized and prioritized within the global pandemic preparedness and response agenda in the future.

Table of Contents



Front Matter Summary 1 Introduction: The Imperative for Global Investment in Influenza Vaccines 2 The Existing Global Governance Landscape for Influenza Vaccines 3 Pathogen Sharing for Influenza Vaccine Production 4 Technology and Manufacturing Partnerships 5 Influenza Vaccine Access and Financing 6 Recommendations and the Path Forward Appendix A: Committee and Staff Biographies Appendix B: Committee Meeting Agendas
Acronyms And Abbreviations xxi
Summary 1(20)
1 Introduction: The Imperative For Global Investment In Influenza Vaccines
21(18)
What If 2020 Had Been the "Year of Influenza" Instead?
23(5)
A Disruptive Moment to Reconsider Influenza in the Wider Pandemic Preparedness Landscape
28(3)
Charge to the Committee on Global Coordination, Partnerships, and Financing
31(2)
Structure of the Report
33(2)
References
35(4)
2 The Existing Global Governance Landscape For Influenza Vaccines
39(20)
World Health Organization and the Influenza "Regime Complex"
39(1)
Governance Gaps Exposed in the 2009 H1N1 "Swine Flu" Pandemic
40(4)
Expanding and Enhancing Influenza Surveillance Since 2009
44(3)
A Snapshot of Current Influenza Vaccine Governance Structures and Frameworks
47(5)
The Global Influenza Strategy and the Governance Path Forward
52(3)
Key Findings and Conclusions
55(1)
References
56(3)
3 Pathogen Sharing For Influenza Vaccine Production
59(20)
The Essential Need for Pathogen Sharing
59(2)
The Critical Importance of Access and Benefit Sharing
61(1)
Equity and Human Rights
62(1)
Existing International Instruments for ABS
63(5)
Barriers and Gaps That Affect ABS for Influenza
68(3)
How Has the "COVID-19 Lens" Changed the Way Governments, Organizations, and Institutions Look at ABS Instruments?
71(3)
Key Findings and Conclusions
74(1)
References
75(4)
4 Technology And Manufacturing Partnerships
79(36)
Platform Technologies in the COVID-19 Era
79(4)
New Industry Partnerships During COVID-19
83(1)
The Current State of Influenza Vaccine Manufacturing and the Limitations of Egg-Based Vaccines
83(2)
New Technologies for Influenza on the Horizon
85(2)
Accelerating the Development of Platform Technologies for Influenza
87(4)
Geographically Distributed and Regional Manufacturing Models ("Hubs")
91(2)
Capabilities Required for the Transition to Platform Technologies
93(1)
Barriers and Pathways to Success for Effective Global Partnerships to Support Next-Generation Influenza Vaccines
94(14)
Key Findings and Conclusions
108(2)
References
110(5)
5 Influenza Vaccine Access And Financing
115(40)
The CO VAX Facility and Its Shortfalls
115(4)
Approaching Equity in Vaccine Access for Influenza
119(1)
Lessons from the COVID-19 Vaccine Experience
120(1)
How Has Pandemic Financing Changed During COVID-19?: Funding for COVID-19 Preparedness and Response
121(6)
Financing PPR: Economic Principles
127(3)
IPPPR's Argument About PPR Financing
130(1)
Scale of Investment Needed to Improve Global PPR
130(3)
Strategies to Drive Investment in Influenza Preparedness and Response: Engaging High- and Middle-Income Countries
133(1)
Key Considerations in Determining Scale and Incentives for Financing PPR
134(15)
Key Findings and Conclusions
149(2)
References
151(4)
6 Recommendations And The Path Forward
155(36)
Situating Influenza in the Broader Pandemic Preparedness and Response Context
155(4)
Conclusions and Recommendations
159(24)
The Path Forward
183(5)
References
188(3)
APPENDIXES
A Committee And Staff Biographies
191(12)
B Committee Meeting Agendas
203